IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia

  • Biomedicines. 2024 Jan 1;12(1):89. doi: 10.3390/biomedicines12010089.
Jonathan Paolino  1  2 ,  Harrison K Tsai  3 ,  Marian H Harris  3 ,  Yana Pikman  1  2
Affiliations
  • 1. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • 2. Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
  • 3. Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
Abstract

IKZF1 encodes the transcription factor IKAROS, a zinc finger DNA-binding protein with a key role in lymphoid lineage development. IKAROS plays a critical role in the development of lineage-restricted mature lymphocytes. Deletions within IKZF1 in B-cell Acute Lymphoblastic Leukemia (B-ALL) lead to a loss of normal IKAROS function, conferring leukemic stem cell properties, including self-renewal and subsequent uncontrolled growth. IKZF1 deletions are associated with treatment resistance and inferior outcomes. Early identification of IKZF1 deletions in B-ALL may inform the intensification of therapy and other potential treatment strategies to improve outcomes in this high-risk leukemia.

Keywords
B-cell acute lymphoblastic leukemia; IKAROS; IKZF1.